187 related articles for article (PubMed ID: 30217378)
21. Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Zhang L; Yan X; Nandy P; Willmann S; Fox KAA; Berkowitz SD; Sharma A; Hermanowski-Vosatka A; Schmidt S; Weitz JI; Garmann D; Peters G
Ther Adv Cardiovasc Dis; 2019; 13():1753944719863641. PubMed ID: 31364490
[TBL] [Abstract][Full Text] [Related]
22. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
[TBL] [Abstract][Full Text] [Related]
24. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Weitz JI
Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
[TBL] [Abstract][Full Text] [Related]
25. Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis.
Wu CT; Chen B; Wang JW; Yen SH; Huang CC
J Orthop Surg Res; 2018 Jul; 13(1):173. PubMed ID: 29996862
[TBL] [Abstract][Full Text] [Related]
26. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
[TBL] [Abstract][Full Text] [Related]
27. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.
Geller BJ; Mega JL; Morrow DA; Guo J; Hoffman EB; Gibson CM; Ruff CT
J Thromb Thrombolysis; 2014 Apr; 37(3):310-6. PubMed ID: 23860881
[TBL] [Abstract][Full Text] [Related]
28. Dual pathway therapy in acute coronary syndrome.
Stachon P; Ahrens I; Bode C; Zirlik A
J Thromb Thrombolysis; 2016 Aug; 42(2):254-60. PubMed ID: 26660521
[TBL] [Abstract][Full Text] [Related]
29. Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
Zeymer U; Schrage B; Westermann D
Thromb Haemost; 2018 Sep; 118(9):1528-1534. PubMed ID: 30103248
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban: An Evaluation of its Cardiovascular Benefit-Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons.
Ageno W
Drugs R D; 2015 Dec; 15(4):295-306. PubMed ID: 26416655
[TBL] [Abstract][Full Text] [Related]
32. Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
Ferreira JP; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; La Police DA; Cleland JGF; Greenberg B; Zannad F
Eur J Heart Fail; 2021 Apr; 23(4):648-656. PubMed ID: 32959502
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
Bauersachs R; Zannad F
Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
[TBL] [Abstract][Full Text] [Related]
34. Novel direct-acting anticoagulants for risk reduction in ACS.
Dobesh PP; Oestreich JH
J Pharm Pract; 2013 Aug; 26(4):358-66. PubMed ID: 23172897
[TBL] [Abstract][Full Text] [Related]
35. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Obonska K; Navarese EP; Lansky A; Tarantini G; Rossini R; Kozinski M; Musumeci G; Di Pasquale G; Górny B; Szczesniak A; Kowalewski M; Gurbel PA; Kubica J
Atherosclerosis; 2013 Aug; 229(2):482-8. PubMed ID: 23672879
[TBL] [Abstract][Full Text] [Related]
36. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome.
Daaboul Y; Korjian S; Plotnikov AN; Burton P; Braunwald E; Wiviott SD; Gibson CM
J Am Coll Cardiol; 2018 Mar; 71(9):1048-1049. PubMed ID: 29495985
[No Abstract] [Full Text] [Related]
39. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
40. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
